On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
We received an updated WNV package insert; please note the manufacturer and license number has been ...